Premium
Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder
Author(s) -
Shioiri T.,
Fujii K.,
Someya T.,
Takahashi S.
Publication year - 1996
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1996.tb10624.x
Subject(s) - pharmacotherapy , panic disorder , medicine , agoraphobia , alprazolam , panic , gastroenterology , endocrinology , cholesterol , psychiatry , anxiety
Shioiri T, Fuji K, Someya T, Takahashi S. Effect of pharmacotherapy on serum cholesterol levels in patients with panic disorder. Acta Psychiatr Scand 1996: 93: 164–167. © Munksgaard 1996. It is unclear whether elevated cholesterol level is a complication of panic disorder (PD) or is associated with pharmacotherapy. We compared the total cholesterol (TC) level in 47 PD patients with that in 47 gender‐ and age‐matched normal controls (NC), and we also examined the pre‐ and post‐treatment TC levels. There was no sex difference in TC. Before pharmacotherapy, the mean TC level in the PD group (194.9 ± 39.6 mg/dl) was non‐significantly higher than that in the NC group (190.5±26.7 mg/dl). The mean TC level in the PD group was significantly reduced following the pharmacotherapy (post‐TC: 184.7± 31.0 mg/dl; t = 2.44, P<0.02), and the subgroup treated with alprazolam ( n = 26 ) showed markedly significant decrease of TC after the treatment ( t = 2.36, P<0.03). The TC level in the PD subgroup with agoraphobia ( n = 24, 198.9 ± 37.9 mg/dl) was slightly higher than that in the group without agoraphobia ( n = 23, 190.8±41.6 mg/dl). These findings suggest that there is a relationship between cholesterol levels and treatment in PD.